GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about change in Management
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has informed the stock exchanges that Ms. Sukanya Choudhury, Executive Vice President - Regulatory Affairs, has been seconded to a group-level role as Regulatory Head, Growth Emerging Markets within the GSK network. The secondment is for a period of 16 months, effective 1st May 2025. As a result, she ceases to be Senior Management Personnel of GlaxoSmithKline Pharmaceuticals India from that date. The filing is made under Regulation 30 of SEBI LODR. The change is an internal transition within the GSK group rather than an exit from the company network.
This is a routine internal secondment within the GSK group, not a resignation. The role is temporarily vacated, and the company may appoint or assign responsibilities to another person internally. Minimal impact expected on stock price or shareholder value.